Pfizer, Uber and Starbucks Highlight Another Busy Earnings Week

Pfizer, Uber and Starbucks Highlight Another Busy Earnings Week

Pfizer Inc., PFE 3.69% Uber UBER -1.15% Technologies Inc. and Starbucks Corp. SBUX 2.13% are among the heavyweights headlining another busy earnings week as investors search for insight into the state of the broader economy. Nearly a third of the S&P 500, or about 160 component companies, is slated to report earnings in the coming week, according to … Read more

Pfizer aims for Covid vaccine price of at least $110 per dosage

Pfizer aims for Covid vaccine price of at least $110 per  dosage

Pfizer Inc. gave some details about its plans to sell the Covid-19 vaccine it developed with BioNTech SE on the commercial market in the United States, saying it expects to price the shot at $110 to $130 per dose for adults. The drugmaker is still negotiating with health insurers but expects the discussions to lead … Read more

FDA approves Novavax Covid-19 Shot as booster for adults

FDA approves Novavax Covid-19 Shot as booster for adults

The Food and Drug Administration gave Novavax emergency approval Inc.’s Covid-19 shot as a booster for adults. The shot targets the original strain of the virus, whereas the updated booster shots from Moderna Inc. and Pfizer Inc. and its partner BioNTech SE, approved in August by the FDA, targeting both the original strain and newer … Read more

Pfizer’s new Omicron targeting booster produces strong immune response

Pfizer’s new Omicron targeting booster produces strong immune response

The redesigned Covid-19 booster from Pfizer Inc. and BioNTech SE generated a strong immune response against the Omicron substrains BA.4 and BA.5, the companies said. The data, which the companies reported in a press release Thursday, provides the first window into how the new images rolling out across the U.S. are faring. An early look … Read more

Merck’s Patent Cliff doesn’t look so scary anymore

Merck’s Patent Cliff doesn’t look so scary anymore

Many of the country’s largest pharmaceutical companies, from Merck MRK 1.17% & Co. to Bristol Myers Squibb, BMY 2.31% are under pressure to make deals right now because they are staring at huge patent cliffs for their best-selling drugs. For investors considering whether to buy into these companies, figuring out which management teams are going … Read more

AstraZeneca eyes cancer, RSV drugs for growth as demand for Covid vaccine wanes

AstraZeneca eyes cancer, RSV drugs for growth as demand for Covid vaccine wanes

AstraZeneca PLC produced one of the world’s most widely used Covid-19 vaccines. As demand for the shot ebbs, the company is focusing on tackling breast cancer and another respiratory virus. Now the company is scaling back production of its vaccine while lining up sequels to some blockbusters that have helped drive the company’s growth in … Read more

The world’s most expensive drugs cannot cure what is wrong with this biotechnology

The world’s most expensive drugs cannot cure what is wrong with this biotechnology

Bluebird Bio BLUE 11.05% is becoming the seller of the two most expensive drugs in the United States and by extension the world, each bringing in nearly $3 million annually. While the high price tag is already leading to public backlash, one would think that the company and its investors would at least see a … Read more

Pfizer requests authorization for children’s Covid-19 Booster

Pfizer requests authorization for children’s Covid-19 Booster

Pfizer Inc. and BioNTech SE asked US health authorities to clear the use of its updated Covid-19 booster in children aged 5 to 11 years. The companies made the request Monday as reformulated shots for people 12 and older roll out across the country. Health officials are urging people to get shots to increase protection … Read more

Moderna Covid-19 Booster shortage leads to fewer appointments at pharmacies

Moderna Covid-19 Booster shortage leads to fewer appointments at pharmacies

Some US pharmacies and other vaccine providers only offer the new Covid-19 booster shot from Pfizer Inc. and BioNTech SE, after a manufacturing quality issue at a contract manufacturer caused shortages at Moderna Inc.’s new booster shot. In recent days, federal officials have informed state officials that there is a limited supply of Moderna’s updated … Read more

A chronic disease that is still waiting for a drug

A chronic disease that is still waiting for a drug

Drug companies have developed treatments for some of the rarest diseases that affect a small percentage of the population, yet they have repeatedly failed to get a drug to market for a chronic and increasingly common disease. As biotech companies take new shots at targets for the liver disease known as NASH, or non-alcoholic steatohepatitis, … Read more